As advised via PHARMAC Tender Results of 30 April 2019 there is to be a change in the listing and future sole supply of Clindamycin hydrochloride capsules 150 mg

New listing from 1 November 2019

Dalacin-C Caps 150 mg 24                                                                              Pharmacode TBA                     Schedule price $4.61

Incumbent brand

Clindamycin ABM Cap 150 mg 16                                                                Pharmacode 2397501                       Schedule price $4.10

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 April 2020.

Brand switch fee for Community Pharmacy not advised.

As of the date of this notification ProPharma / PWR cannot accept Clindamycin Caps ABM for credit under any circumstances.

From 1 November 2019 community pharmacies dispensing Clindamycin hydrochloride caps 150 mg will need to support patients changing to the new brand and manage stock during the transition.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

Benefit of staying with incumbent while stock remains available are minimal, but every cent counts:-

Clindamycin ABM : – Average dispensing is 16. Therefore 1 x @ $4.10 x 3% = $0.1230 plus  $0.253 (pack fee) giving you $0.3760

Compared to ($4.61/24*16) $3.07 x 3% = $0.0921 plus $0.253 (pack fee) giving you $0.3451

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 April 2020. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 April 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.


About The Author